688331.SS SHH
RemeGen Co. Ltd. Class A
1W: -6.2%
1M: -3.6%
3M: -16.4%
YTD: +10.0%
1Y: +87.4%
3Y: +78.5%
¥117.34 ($17.50)
+0.67 (+0.57%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#8
of 155
Biotechnology
Technical Signal Map
6 Bullish
0 Neutral
7 Bearish
688331.SS
$65B
RemeGen Co. Ltd. Class A
BEARISH
-50
002821.SZ
$63B
Asymchem Laboratories (Tianjin) Co., Ltd.
BULLISH
+100
300347.SZ
$57B
Hangzhou Tigermed Consulting Co., Ltd
BULLISH
+91
688578.SS
$50B
Shanghai Allist Pharmaceuticals Co., Ltd.
BULLISH
+87
9926.HK
$100B
Akeso, Inc.
BULLISH
+84
2269.HK
$232B
WuXi Biologics (Cayman) Inc.
BULLISH
+66
300759.SZ
$87B
Pharmaron Beijing Co., Ltd.
BULLISH
+59
6990.HK
$114B
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LEAN BEAR
-11
002422.SZ
$65B
Sichuan Kelun Pharmaceutical Co., Ltd. Class A
LEAN BEAR
-24
1801.HK
$171B
Innovent Biologics, Inc.
BEARISH
-42
9995.HK
$43B
RemeGen Co., Ltd.
BEARISH
-42
1530.HK
$41B
3SBio Inc.
BEARISH
-49
002653.SZ
$70B
Haisco Pharmaceutical Group Co., Ltd.
BEARISH
-66
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| 688331.SS RemeGen Co. Ltd. Class A | $65B | 11.3 | 109.1 | 140.3 | 83.4 | 286.2 | 7 | BEARISH | 87.4 |
| 002821.SZ Asymchem Laboratories (Tianjin) Co., Ltd. | $63B | 65.0 | 5.9 | 10.1 | 12.0 | 12.6 | 4 | BULLISH | 92.7 |
| 300347.SZ Hangzhou Tigermed Consulting Co., Ltd | $57B | 730.0 | 0.5 | 3.2 | -24.2 | 12.2 | 6 | BULLISH | -10.5 |
| 688578.SS Shanghai Allist Pharmaceuticals Co., Ltd. | $50B | 18.8 | 36.7 | 59.1 | 52.1 | 40.8 | 5 | BULLISH | 18.5 |
| 9926.HK Akeso, Inc. | $100B | -87.6 | -26.2 | -26.7 | -23.5 | -5.1 | 2 | BULLISH | -35.5 |
| 2269.HK WuXi Biologics (Cayman) Inc. | $232B | 38.5 | 20.8 | 28.7 | 20.7 | 29.7 | 9 | BULLISH | 77.0 |
| 300759.SZ Pharmaron Beijing Co., Ltd. | $87B | 46.4 | 11.2 | 7.8 | 10.3 | 15.9 | 5 | BULLISH | 58.4 |
| 6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | $114B | — | — | — | — | — | — | LEAN BEAR | — |
| 002422.SZ Sichuan Kelun Pharmaceutical Co., Ltd. Class A | $65B | 35.2 | 7.6 | 6.3 | 14.7 | -4.2 | 3 | LEAN BEAR | 12.0 |
| 1801.HK Innovent Biologics, Inc. | $171B | 116.0 | 14.2 | 72.6 | 14.5 | 116.5 | 8 | BEARISH | 0.3 |
| 9995.HK RemeGen Co., Ltd. | $43B | 11.3 | 108.4 | 139.6 | 83.4 | 283.5 | 7 | BEARISH | -5.5 |
| 1530.HK 3SBio Inc. | $41B | 4.1 | 50.7 | 106.2 | 25.3 | 68.2 | 7 | BEARISH | -52.7 |
| 002653.SZ Haisco Pharmaceutical Group Co., Ltd. | $70B | 70.8 | 22.1 | 14.4 | 19.4 | 35.9 | 7 | BEARISH | 4.6 |
| 688331.SS RemeGen Co. Ltd. Class A | $65B | 11.3 | 109.1 | 140.3 | 83.4 | 286.2 | 7 | BEARISH | 87.4 |
| 002821.SZ Asymchem Laboratories (Tianjin) Co., Ltd. | $63B | 65.0 | 5.9 | 10.1 | 12.0 | 12.6 | 4 | BULLISH | 92.7 |
| 300347.SZ Hangzhou Tigermed Consulting Co., Ltd | $57B | 730.0 | 0.5 | 3.2 | -24.2 | 12.2 | 6 | BULLISH | -10.5 |
| 688578.SS Shanghai Allist Pharmaceuticals Co., Ltd. | $50B | 18.8 | 36.7 | 59.1 | 52.1 | 40.8 | 5 | BULLISH | 18.5 |
| 9926.HK Akeso, Inc. | $100B | -87.6 | -26.2 | -26.7 | -23.5 | -5.1 | 2 | BULLISH | -35.5 |
| 2269.HK WuXi Biologics (Cayman) Inc. | $232B | 38.5 | 20.8 | 28.7 | 20.7 | 29.7 | 9 | BULLISH | 77.0 |
| 300759.SZ Pharmaron Beijing Co., Ltd. | $87B | 46.4 | 11.2 | 7.8 | 10.3 | 15.9 | 5 | BULLISH | 58.4 |
| 6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | $114B | — | — | — | — | — | — | LEAN BEAR | — |
| 002422.SZ Sichuan Kelun Pharmaceutical Co., Ltd. Class A | $65B | 35.2 | 7.6 | 6.3 | 14.7 | -4.2 | 3 | LEAN BEAR | 12.0 |
| 1801.HK Innovent Biologics, Inc. | $171B | 116.0 | 14.2 | 72.6 | 14.5 | 116.5 | 8 | BEARISH | 0.3 |
| 9995.HK RemeGen Co., Ltd. | $43B | 11.3 | 108.4 | 139.6 | 83.4 | 283.5 | 7 | BEARISH | -5.5 |
| 1530.HK 3SBio Inc. | $41B | 4.1 | 50.7 | 106.2 | 25.3 | 68.2 | 7 | BEARISH | -52.7 |
| 002653.SZ Haisco Pharmaceutical Group Co., Ltd. | $70B | 70.8 | 22.1 | 14.4 | 19.4 | 35.9 | 7 | BEARISH | 4.6 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
688331.SS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F